<DOC>
	<DOCNO>NCT02678143</DOCNO>
	<brief_summary>The aim study evaluate overall safety feasibility use haploidentical one antigen mismatch unrelated hematopoietic stem cell transplant ( HSCT ) adult patient severe sickle cell disease ( SCD ) undergo non-myeloablative preparative regimen consist total body irradiation ( TBI ) , cyclophosphamide alemtuzumab graft vs. host disease ( GvHD ) prophylaxis consist post-transplant cyclophosphamide ( PT-Cy ) , mycophenolate mofetil ( MMF ) , sirolimus . The investigator anticipate approach expand donor pool offer safe less toxic curative intervention .</brief_summary>
	<brief_title>Nonmyeloablative Conditioning Mismatched Hematopoietic Stem Cell Transplantation Severe Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Recipient Diagnosis sickle cell disease ( HB SS , SC , SBetathal ( 0 ) ) ; confirm hemoglobin electrophoresis , highperformance liquid chromatography , DNA test necessary . At high risk diseaserelated morbidity mortality , define severe endorgan damage ( one A , B , C , D ) potentially modifiable complication ( ) ameliorate hydroxyurea ( E ) : Stroke ( define clinically significant neurologic event accompany infarct cerebral MRI cerebral arteriopathy require chronic transfusion therapy ) Sickle cellrelated renal insufficiency kidney biopsy consistent sickle cell nephropathy nephrotic syndrome . Pulmonary hypertension ( define tricuspid regurgitant jet velocity ( TRV ) ≥2.5 m/s baseline ( without vasoocclusive crisis ) ) Sickle hepatopathy ( define direct bilirubin &gt; 0.4 mg/dL explain severe acute hemolysis , viral hepatitis , extrahepatic obstruction , hepatic sequestration . ) Any one complication ameliorate hydroxyurea maximum tolerate dose least 6 month : Vasoocclusive crisis 1 hospital admission per year maximal tolerate dose hydroxyurea Acute chest syndrome occur hydroxyurea Age great equal 19 year . Availability one antigen mismatch unrelated haploidentical relate donor Ability comprehend willing sign inform consent Recipient Detectable antibody ABO , Rh , red blood cell antigen donor Presence donor specific antibody detect donor specific antibody screen ( use product haploidentical donor ) . ECOG performance status ≥ 3 . Evidence uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical symptom ) within one month prior start condition regimen . Patients fever suspect minor infection await resolution symptom start condition regimen . Poor cardiac function define leave ventricular ejection fraction &lt; 35 % . Poor pulmonary function define FEV1 FVC &lt; 40 % predict . Pulmonary hypertension moderate severe echocardiographic standard . Poor liver function define direct bilirubin &gt; 3.1 mg/dl Poor kidney function define creatinine clearance &lt; 70mL/min . HIVpositive . Prior transfusion donor recipient cause alloimmunization vs. donor cell . Pregnant breastfeeding . Diagnosis debilitate medical psychiatric illness would preclude give informed consent receive optimal treatment followup . Donor Selection : Must one antigen mismatch unrelated donor firstdegree relative share least one HLA haplotype recipient . Must SCD another hemoglobinopathy . In good health base institutional standard . Weight ≥ 20kg . If donor &lt; 18 year old must ability give inform assent base institutional standard pediatric donor . Able undergo peripheral blood stem cell mobilization GCSF Hemoglobin S ≤ 50 % . HIV1 &amp; 2 antibody , HTLVI &amp; II antibody , HBV HCV seronegative . Note : When one donor available , donor low number HLA allele mismatch choose , unless HLA crossmatch incompatibility medical reason select otherwise , case donor selection responsibility PI , consultation immunogenetics laboratory . In case one donor least degree mismatch , donor select base favorable combination ( ) HLA compatibility crossmatch testing , ( ii ) ABO compatibility , ( iii ) CMV status ( iv ) noninherited maternal antigen ( NIMAs ) mismatching . HLA crossmatching ( order priority ) Mutually compatible ( crossmatching antibody ) Recipient noncrossreactive donor , donor crossreactive recipient Mutually crossreactive ABO compatibility ( order priority ) Compatible Major incompatibility Minor incompatibility Major minor incompatibility CMV negative donor prefer NIMA mismatch donor prefer</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>